The company's financial position has deteriorated significantly, with equity falling to a negative $6.4M by 2025Q4 and a current ratio of only 0.17, signaling acute insolvency risk.
| Total Current Assets | 7.12M | 1.31M | 147.99K | 81.22K | 1.1M | 293.22K |
| Cash & Short-Term Investments | 5.86M | 1M | 3.63K | 11.17K | 497.26K | 0 |
| Cash Only | 5.86M | 1M | 3.63K | 0 | 497.26K | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 36.5K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 369.97K | 253.16K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 2.08K | 14.63K | - | - | - | - |
| Other Current Assets | 890.15K | 55.1K | 107.85K | 70.05K | 600.49K | 293.22K |
| Total Non-Current Assets | 0 | 0 | 6.67M | 19.9M | 299.08M | 293.22K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 6.67M | 19.9M | 299K | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 298.79M | 293.22K |
| Total Assets | 7.12M | 1.31M | 147.99K | 19.98M | 300.18M | 293.22K |
| Asset Turnover | 0.01x | 0.00x | - | - | - | - |
| Asset Growth % | 899.24% | 786.66% | -99.26% | -93.34% | 102273.98% | - |
| Total Current Liabilities | 3.15M | 7.59M | 1.69M | 403.33K | 303.32K | 293.7K |
| Accounts Payable | 857.92K | 1.01M | 310.22K | 152K | 180.63K | 273 |
| Days Payables Outstanding | 13.52K | 58.6K | - | - | - | - |
| Short-Term Debt | 499.21K | 1.38M | 1.27M | 12.38K | 27.97K | 238.6K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 80 | 0 |
| Other Current Liabilities | 1.8M | 4.84M | 111.03K | 0 | -28.05K | 0 |
| Current Ratio | 2.26x | 0.17x | 0.09x | 0.20x | 3.62x | 1.00x |
| Quick Ratio | 2.14x | 0.14x | 0.09x | 0.20x | 3.62x | 1.00x |
| Cash Conversion Cycle | -11.44K | - | - | - | - | - |
| Total Non-Current Liabilities | 96.25K | 95.66K | 0 | 0 | 10.81M | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 96.25K | 95.66K | 0 | 0 | 10.81M | 0 |
| Total Liabilities | 3.25M | 7.69M | 1.69M | 403.33K | 11.12M | 293.7K |
| Total Debt | 499.21K | 1.38M | 1.27M | 12.38K | 27.97K | 238.6K |
| Net Debt | -5.36M | 380.87K | 1.26M | 12.38K | -497.26K | 238.6K |
| Debt / Equity | 0.13x | - | - | 0.00x | 0.00x | - |
| Debt / EBITDA | -0.12x | - | - | - | 0.01x | 103.24x |
| Net Debt / EBITDA | 1.32x | - | - | - | -0.15x | 103.24x |
| Interest Coverage | -0.54x | -2.27x | -13.06x | 498.88x | - | - |
| Total Equity | 3.87M | -6.38M | -1.54M | 19.58M | 289.07M | -475 |
| Equity Growth % | -14592.62% | -314.02% | -107.87% | -93.23% | 60856138.32% | - |
| Book Value per Share | 2.59 | -4.27 | -2.23 | 40.83 | 321.74 | -0.00 |
| Total Shareholders' Equity | 3.87M | -6.38M | -1.54M | 19.58M | 289.07M | -475 |
| Common Stock | 17 | 353 | 169.99K | 19.9M | 299M | 718 |
| Retained Earnings | -30.48M | -27.26M | -2.78M | -11.29M | -9.94M | -25.48K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent insolvency and dilution
As reported in recent financial filings, ASBPW's equity position has deteriorated from a positive $19.6M in 2023Q4 to a negative $6.4M by 2025Q4, illustrating a rapid depletion of shareholder value that underscores the company's inability to sustain its operations through internal capital generation.
The consistent decline in total assets alongside the accumulation of negative retained earnings suggests that the company is consuming its capital base to fund ongoing operating losses. This trajectory indicates that the business model has failed to reach a self-sustaining scale, leaving the balance sheet in a state of terminal decline.
Based on the provided quarterly data, ASBPW's current ratio has plummeted to 0.17 as of 2025Q4, reflecting a severe inability to cover short-term obligations with existing liquid assets and highlighting an acute risk of insolvency in the near term.
The company's cash position, which dropped to $1M in 2025Q4, appears insufficient to support the high burn rate identified in previous periods. Investors should monitor the company's ability to secure emergency financing, as the current liquidity buffer provides almost no margin for operational error or regulatory delays.
According to the balance sheet records, ASBPW has transitioned into a negative equity position, with retained earnings falling to -$27.3M by 2025Q4, which suggests that historical capital allocation has failed to generate any meaningful return on invested capital for shareholders.
The shift into negative equity is a significant red flag that typically precedes restructuring or liquidation events in the biotechnology sector. This condition implies that the company's liabilities now exceed its total assets, effectively rendering the common equity interest subordinate to the claims of creditors.
As indicated by the historical balance sheet, the absence of tangible assets like PPE, combined with the previous presence of $5M in goodwill, suggests that the company's asset base is highly speculative and lacks the physical infrastructure required for commercial-scale diagnostic manufacturing.
The reliance on intangible assets and the lack of productive capital suggest that the balance sheet is highly sensitive to impairment risks. If the company's proprietary assays fail to achieve clinical validation, the remaining asset value may be effectively zero, leaving little to no recovery value for stakeholders.
Quick answers to the most common questions about buying ASBPW stock.
As of 2025, Aspire Biopharma Holdings, Inc. (ASBPW) had total assets of $1.3M including $1.3M in current assets.
Aspire Biopharma Holdings, Inc. (ASBPW) carries total debt of $1.4M, offset by $1.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Aspire Biopharma Holdings, Inc. (ASBPW) has total shareholders' equity (book value) of $-6.4M ($-4.27 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Aspire Biopharma Holdings, Inc. (ASBPW) reported a current ratio of 0.17x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.